Business Context and Reporting Period
Company: Jazz Pharmaceuticals Plc (Ireland)
Filing Type: Form 8-K (Current Report)
Date: December 19, 2013
Event: Entry into a Material Definitive Agreement to acquire Gentium S.p.A.
Key Financial Metrics and Transaction Terms
- Offer Price: $57.00 per Company Share (Ordinary Shares and ADSs) in cash, net to seller.
- Financing Commitment: $500.0 million in incremental term loans committed by Barclays Bank PLC.
- Termination Fees (Payable by Gentium):
- Approximately $25.3 million if Gentium accepts a superior offer.
- Approximately $10.1 million if Gentium changes its recommendation in favor of the Offer.
- Additional $15.2 million if Gentium enters an alternative transaction within one year of termination.
- Financial Performance: The filing text does not provide specific revenue, profit, cash flow, or margin data for Jazz Pharmaceuticals or Gentium.
Material Changes and Conditions
The filing announces a strategic shift via a tender offer to acquire all outstanding shares of Gentium S.p.A. Key conditions for the offer include:
- Minimum Tender Condition: At least 66 2/3% of fully diluted Company Shares must be validly tendered (Jazz may lower this to a majority at its discretion).
- Financing Condition: The offer is not subject to a financing condition, though the $500 million debt commitment is subject to customary closing conditions.
- Post-Closing Actions: Jazz intends to delist Gentium ADSs from NASDAQ and terminate the deposit agreement, likely resulting in no active trading market for remaining shares.
Outlook, Risks, and Management Commentary
Management Commentary: Jazz and Gentium issued a joint press release and investor presentation regarding the transaction. An investor call was scheduled for December 19, 2013.
Risks and Contingencies:
- Completion Risk: No assurance that the tender offer or debt financing will be completed on anticipated terms or at all.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the timing and benefits of the transaction, which are subject to significant risks and uncertainties.
- Representations: Representations in the Tender Offer Agreement are qualified by confidential disclosure schedules and are for risk allocation, not necessarily factual characterizations.
Investor Verification Checklist
- Verify the final terms of the Tender Offer Agreement once filed as an amendment to this 8-K.
- Review the definitive documentation for the $500 million incremental term loan facility.
- Monitor the tender offer materials (Schedule TO) and Gentium's Solicitation/Recommendation Statement (Schedule 14D-9) for detailed risk factors and voting instructions.
- Confirm the status of the 66 2/3% minimum tender condition prior to the closing of the offer.
- Assess the impact of the potential delisting of Gentium ADSs on remaining shareholders.